Biomarker & Intervention Discovery

Alcohol Use Disorder

This page lists 7 druggable gene targets, 40 approved or trial-tested drug candidates and 15 recent clinical trials for Alcohol Use Disorder, with each agent ranked by the strength of its evidence (clinical, mechanistic or correlative). Candidates include existing drugs that could be repurposed. Sources are linked so you can check every claim.

Spontaneous remission30-40% of people with AUD achieve sustained abstinence without formal treatment at 1 year (natural recovery); but…
Best-intervention remissionNaltrexone (COMBINE trial): 23% abstinence rate vs 14% placebo at 16 weeks; combined pharmacotherapy + CBT: best…
Gap sizeVery large — vast majority of people with AUD never receive pharmacotherapy; <10% receive evidence-based treatment
Primary barrieraccess/framing
Full remission profile →

Remission & chronicity

Spontaneous remission
30-40% of people with AUD achieve sustained abstinence without formal treatment at 1 year (natural recovery); but functional impairment, liver damage, and mortality risk accumulate; relapse in 50-60% within 1 year even after treatment
Best-intervention remission
Naltrexone (COMBINE trial): 23% abstinence rate vs 14% placebo at 16 weeks; combined pharmacotherapy + CBT: best outcomes (~30-40% sustained abstinence at 1 year); acamprosate: reduces relapse risk 14% (meta-analysis); liver cirrhosis reversal with abstinence: fibrosis regression in 30-40% at 5 years
Gap size
Very large — vast majority of people with AUD never receive pharmacotherapy; <10% receive evidence-based treatment
Primary barrier
access/framing
AUD is massively undertreated; only 5.7% of people with AUD in the US received any treatment in 2019 (SAMHSA); naltrexone and acamprosate are dramatically underprescribed (<1% of AUD patients); 12-step/abstinence framing excludes patients seeking harm reduction; primary care providers rarely screen or treat

Biomarker Targets & Therapeutic Agents

Gene targets queried against DGIdb, Open Targets, ChEMBL, PubMed, and Europe PMC. Agents ranked: Clinical > Mechanistic > Correlative.

ALDH2 170DRD2 372GABRA1 302GRIN1 188GRIN2B 236GRM5 233OPRM1 377
Therapeutic Agent Effect Direction Evidence Tier Potency Source
DEHYDRATED ALCOHOL ? unclear Mechanistic
ACETALDEHYDE ? unclear Mechanistic
DISULFIRAM ↓ inhibits Mechanistic 3400.0 nM (IC50)
NALTREXONE ? unclear Mechanistic
PRUNETIN ↓ inhibits Mechanistic 450.0 nM (Ki)
HEROIN ? unclear Mechanistic
DOCETAXEL ANHYDROUS ? unclear Mechanistic
CISPLATIN ? unclear Mechanistic
NITROGLYCERIN ? unclear Mechanistic
MIRIVADELGAT ? unclear Mechanistic
DAIDZIN ↓ inhibits Mechanistic 40.0 nM (IC50)
CHEMBL112007 ↓ inhibits Mechanistic 9.0 nM (IC50)
CHEMBL113617 ↓ inhibits Mechanistic 270.0 nM (IC50)
CHEMBL115314 ↓ inhibits Mechanistic 260.0 nM (IC50)
CHEMBL112165 ↓ inhibits Mechanistic 800.0 nM (IC50)
CHEMBL113640 ↓ inhibits Mechanistic 9.0 nM (IC50)
CHEMBL115092 ↓ inhibits Mechanistic 40.0 nM (IC50)
CHEMBL132065 ↓ inhibits Mechanistic 100.0 nM (IC50)
CHEMBL113123 ↓ inhibits Mechanistic 3.0 nM (IC50)
CHEMBL112437 ↓ inhibits Mechanistic 300.0 nM (IC50)
CHEMBL112696 ↓ inhibits Mechanistic 4.0 nM (IC50)
DAIDZEIN ↓ inhibits Mechanistic 9000.0 nM (IC50)
CHEMBL134275 ↓ inhibits Mechanistic 400.0 nM (IC50)
CHEMBL113855 ↓ inhibits Mechanistic 7200.0 nM (IC50)
CHEMBL262662 ↓ inhibits Mechanistic 130.0 nM (IC50)
CHEMBL113586 ↓ inhibits Mechanistic 100.0 nM (IC50)
CHEMBL112286 ↓ inhibits Mechanistic 2500.0 nM (IC50)
CHEMBL419936 ↓ inhibits Mechanistic 1200.0 nM (IC50)
CHEMBL115161 ↓ inhibits Mechanistic 1700.0 nM (IC50)
CHEMBL109868 ↓ inhibits Mechanistic 250.0 nM (IC50)
CHEMBL110038 ↓ inhibits Mechanistic 3500.0 nM (IC50)
CHEMBL114083 ↓ inhibits Mechanistic 40.0 nM (IC50)
4'-HYDROXYCHALCONE ↓ inhibits Mechanistic 7000.0 nM (IC50)
CHEMBL324628 ↓ inhibits Mechanistic 1000.0 nM (IC50)
CHEMBL112070 ↓ inhibits Mechanistic 280.0 nM (IC50)
CHEMBL113113 ↓ inhibits Mechanistic 70.0 nM (IC50)
CHEMBL113058 ↓ inhibits Mechanistic 120.0 nM (IC50)
CHEMBL326803 ↓ inhibits Mechanistic 130.0 nM (IC50)
CHEMBL112865 ↓ inhibits Mechanistic 240.0 nM (IC50)
CHEMBL111984 ↓ inhibits Mechanistic 150.0 nM (IC50)

Showing top 40 of 170 agents ranked by evidence tier.

Therapeutic Agent Effect Direction Evidence Tier Potency Source
LOXAPINE HYDROCHLORIDE ↓ inhibits Mechanistic
MINAPRINE ↑ activates Mechanistic
SULPIRIDE ↓ inhibits Mechanistic
HALOPERIDOL DECANOATE ↓ inhibits Mechanistic
ZIPRASIDONE MESYLATE ↓ inhibits Mechanistic
METHYLDOPA ANHYDROUS ? unclear Mechanistic
BENPERIDOL ↓ inhibits Mechanistic
FLUSPIRILENE ↓ inhibits Mechanistic
VERALIPRIDE ↓ inhibits Mechanistic
CAFFEINE ? unclear Mechanistic
SUMANIROLE ↑ activates Mechanistic 9.0 nM (Ki)
ZIPRASIDONE ↓ inhibits Mechanistic
METOCLOPRAMIDE HYDROCHLORIDE ? unclear Mechanistic
LUMATEPERONE ↓ inhibits Mechanistic
FLUPENTHIXOL ↓ inhibits Mechanistic
PROCHLORPERAZINE ↓ inhibits Mechanistic
PERAZINE ? unclear Mechanistic
FLUPHENAZINE HYDROCHLORIDE ↓ inhibits Mechanistic
ROPINIROLE ↑ activates Mechanistic
RACLOPRIDE ↓ inhibits Mechanistic
PROMAZINE ↓ inhibits Mechanistic
[3H]PD128907 ↑ activates Mechanistic
MORPHINE SULFATE ? unclear Mechanistic
ALIZAPRIDE ↓ inhibits Mechanistic
PHENYLTOLOXAMINE ? unclear Mechanistic
LOXAPINE ↓ inhibits Mechanistic
CABERGOLINE ↑ activates Mechanistic
BREXPIPRAZOLE ↑ activates Mechanistic
PALIPERIDONE ↓ inhibits Mechanistic
APLINDORE FUMARATE ↑ activates Mechanistic
APOMORPHINE ↑ activates Mechanistic
CARIPRAZINE ↑ activates Mechanistic
MOLINDONE ? unclear Mechanistic
TIAPRIDE ↓ inhibits Mechanistic
ZOTEPINE ↓ inhibits Mechanistic
DOPAMINE ↑ activates Mechanistic
XP21279 ? unclear Mechanistic
PROMAZINE HYDROCHLORIDE ↓ inhibits Mechanistic
VILAZODONE HYDROCHLORIDE ↑ activates Mechanistic
TRIFLUPROMAZINE ↓ inhibits Mechanistic

Showing top 40 of 372 agents ranked by evidence tier.

Therapeutic Agent Effect Direction Evidence Tier Potency Source
PICROTOXIN ? unclear Mechanistic
THIAMYLAL SODIUM ~ modulates Mechanistic
GANAXOLONE ~ modulates Mechanistic
BUTOBARBITAL ? unclear Mechanistic
CHLORDIAZEPOXIDE ~ modulates Mechanistic
CLOBAZAM ~ modulates Mechanistic
CLORAZEPATE ? unclear Mechanistic
TPA023 ~ modulates Mechanistic
ZK-93423 ? unclear Mechanistic
FLUMAZENIL ~ modulates Mechanistic 3.3 nM (Ki)
AMOBARBITAL ? unclear Mechanistic
PAGOCLONE ~ modulates Mechanistic
OXAZEPAM ~ modulates Mechanistic
TETRAHYDRODEOXYCORTICOSTERONE ~ modulates Mechanistic
METHOHEXITAL ? unclear Mechanistic
CLONAZEPAM ~ modulates Mechanistic
[3H]GABAZINE ↓ inhibits Mechanistic
FLURAZEPAM ? unclear Mechanistic
METHARBITAL ~ modulates Mechanistic
LORAZEPAM ~ modulates Mechanistic
RO4938581 ~ modulates Mechanistic
SECOBARBITAL ? unclear Mechanistic
BUTABARBITAL SODIUM ~ modulates Mechanistic
MIDAZOLAM HYDROCHLORIDE ~ modulates Mechanistic
SANDARACOPIMARIC ACID ? unclear Mechanistic
QUAZEPAM ~ modulates Mechanistic
PHENOBARBITAL ? unclear Mechanistic
PRIMIDONE ~ modulates Mechanistic
ISOGUVACINE ↑ activates Mechanistic
ZOLPIDEM TARTRATE ~ modulates Mechanistic
CHEMBL:CHEMBL2170369 ? unclear Mechanistic
ESTAZOLAM ~ modulates Mechanistic
TOPIRAMATE ~ modulates Mechanistic
ETHCHLORVYNOL ~ modulates Mechanistic
CLORAZEPATE DIPOTASSIUM ~ modulates Mechanistic
ZALEPLON ~ modulates Mechanistic
FLUNITRAZEPAM ~ modulates Mechanistic 4.5 nM (Kd)
BUTABARBITAL ? unclear Mechanistic
THIAMYLAL ? unclear Mechanistic
BUTALBITAL ~ modulates Mechanistic

Showing top 40 of 302 agents ranked by evidence tier.

Therapeutic Agent Effect Direction Evidence Tier Potency Source
AV-101 ↓ inhibits Mechanistic
COMPOUND 8 [PMID: 17562362} ↓ inhibits Mechanistic
KETAMINE HYDROCHLORIDE ~ modulates Mechanistic
SERINE, D- ↑ activates Mechanistic
5,7-DICHLOROKYNURENIC ACID ↓ inhibits Mechanistic
PHILANTHOTOXIN 343 ? unclear Mechanistic
FELBAMATE ↓ inhibits Mechanistic
AMANTADINE HYDROCHLORIDE ↓ inhibits Mechanistic
(+)-HA966 ↑ activates Mechanistic
NEBOGLAMINE ~ modulates Mechanistic
AZD8108 ↓ inhibits Mechanistic
CNS-5161 ? unclear Mechanistic
D-SERINE ? unclear Mechanistic
GLYCINE ↑ activates Mechanistic
[3H]CGP39653 ↓ inhibits Mechanistic
EVT-101 ↓ inhibits Mechanistic
DEXANABINOL ? unclear Mechanistic
ORPHENADRINE ? unclear Mechanistic
TRAXOPRODIL ↓ inhibits Mechanistic
ESKETAMINE HYDROCHLORIDE ~ modulates Mechanistic
ESKETAMINE ~ modulates Mechanistic
MEMANTINE HYDROCHLORIDE ~ modulates Mechanistic
DELUCEMINE ↓ inhibits Mechanistic
[3H]L689560 ↓ inhibits Mechanistic
RALFINAMIDE ↓ inhibits Mechanistic
APIMOSTINEL ↑ activates Mechanistic
CYCLOSERINE ? unclear Mechanistic
[3H]CGP61594 ↓ inhibits Mechanistic
GW468816 ↓ inhibits Mechanistic
[3H]CPP ↓ inhibits Mechanistic
LATREPIRDINE ? unclear Mechanistic
NBQX ? unclear Mechanistic
[3H]CGS19755 ↓ inhibits Mechanistic
ORPHENADRINE HYDROCHLORIDE ↓ inhibits Mechanistic
[3H]D-ASPARTIC ACID ↑ activates Mechanistic
ORPHENADRINE CITRATE ↓ inhibits Mechanistic
(RS)-(TETRAZOL-5-YL)GLYCINE ↑ activates Mechanistic
DIZOCILPINE ? unclear Mechanistic
RADIPRODIL ↓ inhibits Mechanistic
PERZINFOTEL ↓ inhibits Mechanistic

Showing top 40 of 188 agents ranked by evidence tier.

Therapeutic Agent Effect Direction Evidence Tier Potency Source
APIMOSTINEL ↑ activates Mechanistic
L701324 ↓ inhibits Mechanistic
FELBAMATE ↓ inhibits Mechanistic
METHYLPHENIDATE ? unclear Mechanistic
CLOZAPINE ? unclear Mechanistic
NVP-AAM077 ↓ inhibits Mechanistic
GLYCINE ↑ activates Mechanistic
SELFOTEL ↓ inhibits Mechanistic
AMANTADINE HYDROCHLORIDE ↓ inhibits Mechanistic
QUETIAPINE FUMARATE ? unclear Mechanistic
L689560 ↓ inhibits Mechanistic
LATREPIRDINE ? unclear Mechanistic
MG2+ ↓ inhibits Mechanistic
TRAXOPRODIL ↓ inhibits Mechanistic 74.0 nM (IC50)
VALPROIC ACID ? unclear Mechanistic
[3H]DIZOCILPINE ↓ inhibits Mechanistic
CNS-5161 ? unclear Mechanistic
NEBOGLAMINE ~ modulates Mechanistic
NP-10679 ? unclear Mechanistic
5,7-DICHLOROKYNURENIC ACID ↓ inhibits Mechanistic
GV196771A ↓ inhibits Mechanistic
DIZOCILPINE ↓ inhibits Mechanistic
INDANTADOL ↓ inhibits Mechanistic
ESKETAMINE HYDROCHLORIDE ~ modulates Mechanistic
SEVOFLURANE ? unclear Mechanistic
LANICEMINE ↓ inhibits Mechanistic
ASPARTIC ACID ↑ activates Mechanistic
UBP141 ↓ inhibits Mechanistic
DELUCEMINE ↓ inhibits Mechanistic
S-DESCHLOROKETAMINE ↓ inhibits Mechanistic
RAPASTINEL ↑ activates Mechanistic
[3H]L689560 ↓ inhibits Mechanistic
EVT-101 ? unclear Mechanistic
[3H]D-ASPARTIC ACID ↑ activates Mechanistic
[3H]MDL105519 ↓ inhibits Mechanistic
ELIPRODIL ? unclear Mechanistic 13.0 nM (Ki)
D-CCPENE ↓ inhibits Mechanistic
N1-DANSYL-SPERMINE ↓ inhibits Mechanistic
ESKETAMINE ~ modulates Mechanistic
KETAMINE HYDROCHLORIDE ↓ inhibits Mechanistic

Showing top 40 of 236 agents ranked by evidence tier.

Therapeutic Agent Effect Direction Evidence Tier Potency Source
[3H]M-MPEP ↓ inhibits Mechanistic
RASEGLURANT ~ modulates Mechanistic
GRN-529 ~ modulates Mechanistic
GLUTAMIC ACID ↑ activates Mechanistic 11400.0 nM (Ki)
FENOBAM ANHYDROUS ~ modulates Mechanistic
COMPOUND 41 [PMID: 23434029] ~ modulates Mechanistic
DIPRAGLURANT ~ modulates Mechanistic
LSN2463359 ~ modulates Mechanistic
MAVOGLURANT ↓ inhibits Mechanistic
COMPOUND 16M [PMID: 19931453] ~ modulates Mechanistic
CDPPB ~ modulates Mechanistic
COMPOUND 13 [PMID: 15686941] ~ modulates Mechanistic
MPEP ~ modulates Mechanistic
AZD6538 ~ modulates Mechanistic
COMPOUND 53 [PMID: 23434029] ~ modulates Mechanistic
GANCICLOVIR ? unclear Mechanistic
STX107 ~ modulates Mechanistic
CPPZ ~ modulates Mechanistic
CTEP ~ modulates Mechanistic
COMPOUND 47 [PMID: 21295468] ~ modulates Mechanistic
BOMA ~ modulates Mechanistic
COMPOUND 24D [PMID: 23357634] ~ modulates Mechanistic
COMPOUND 10 [PMID: 15482906] ~ modulates Mechanistic
CHPG ↑ activates Mechanistic
COMPOUND 11A [PMID: 14697765] ~ modulates Mechanistic
AZD2066 ~ modulates Mechanistic
ADX-47273 ~ modulates Mechanistic
SIB-1757 ~ modulates Mechanistic
MTEB ~ modulates Mechanistic
DEHYDRATED ALCOHOL ? unclear Mechanistic
COMPOUND 30 [PMID: 21757343] ~ modulates Mechanistic
DASOLAMPANEL ETIBUTIL ↓ inhibits Mechanistic
AZD2516 ~ modulates Mechanistic
COMPOUND 10 [PMID: 15482908] ~ modulates Mechanistic
CPPHA ~ modulates Mechanistic
3,3'-DIFLUOROBENZALDAZINE ~ modulates Mechanistic
COMPOUND 18 [PMID: 21927650] ~ modulates Mechanistic
PTEB ~ modulates Mechanistic
VU0409551 ~ modulates Mechanistic
COMPOUND 8 [PMID: 15482908] ~ modulates Mechanistic

Showing top 40 of 233 agents ranked by evidence tier.

Therapeutic Agent Effect Direction Evidence Tier Potency Source
AXOMADOL ↑ activates Mechanistic
BMS-986121 ~ modulates Mechanistic
DEXTROAMPHETAMINE SULFATE ? unclear Mechanistic
METHADONE HYDROCHLORIDE ↑ activates Mechanistic
HYDROCODONE POLISTIREX ↑ activates Mechanistic
CHEMBL:CHEMBL570176 ? unclear Mechanistic
OXYCODONE HYDROCHLORIDE ↑ activates Mechanistic
BEVENOPRAN ↓ inhibits Mechanistic
EG-1-230 ↑ activates Mechanistic
TAPENTADOL ↑ activates Mechanistic
BUTORPHANOL ↑ activates Mechanistic
CTOP ↓ inhibits Mechanistic
NAVACAPRANT ↓ inhibits Mechanistic
NALOXONE HYDROCHLORIDE ↓ inhibits Mechanistic
CODEINE POLISTIREX ↑ activates Mechanistic
LOPERAMIDE ↑ activates Mechanistic
ANILERIDINE ? unclear Mechanistic
LOFENTANIL ↑ activates Mechanistic
LEVOMETHADYL ACETATE HYDROCHLORIDE ↑ activates Mechanistic
DEZOCINE ↑ activates Mechanistic
FENTANYL HYDROCHLORIDE ↑ activates Mechanistic
QUADAZOCINE ↓ inhibits Mechanistic
OXYMORPHONE ? unclear Mechanistic
NALDEMEDINE TOSYLATE ↓ inhibits Mechanistic
ALFENTANIL HYDROCHLORIDE ↑ activates Mechanistic
ANTICONVULSANT AGENT ? unclear Mechanistic
FENTANYL CITRATE ↑ activates Mechanistic
NALTREXONE ↓ inhibits Mechanistic
NALMEFENE ↓ inhibits Mechanistic
REMIFENTANIL HYDROCHLORIDE ? unclear Mechanistic
OXYCODONE ↑ activates Mechanistic
NALTRIBEN ↓ inhibits Mechanistic
PAREGORIC ↑ activates Mechanistic
OXYMORPHONE HYDROCHLORIDE ↑ activates Mechanistic
ATOXIFENT ↑ activates Mechanistic
DYNORPHIN A ↑ activates Mechanistic
ERGOT ALKALOIDS ? unclear Mechanistic
ALVIMOPAN ANHYDROUS ↓ inhibits Mechanistic
METHYLSAMIDORPHAN ↓ inhibits Mechanistic
DYNORPHIN A-(1-13) ↑ activates Mechanistic

Showing top 40 of 377 agents ranked by evidence tier.


Clinical Trials

Drug, biologic and supplement trials (treatment or prevention) from ClinicalTrials.gov whose main condition is Alcohol Use Disorder: recruiting, active or completed, most recently updated first. Data retrieved 2026-10-28.

NCT06679062 Phase: 2 Started: 2025-07-16

This study is to determine if suvorexant (SUV) will reduce insomnia in 76 men and women veteran and non-veterans between the ages 21-65 with posttraumatic stress disorder (PTSD) symptoms and alcohol use disorder (AUD). All participants will have a 7-day placebo run-in period, followed by a random as...

NCT07219953 Phase: 3 Started: 2025-10-16

The purpose of this study is to see if brenipatide when compared to a placebo works and is safe for participants with Alcohol Use Disorder (AUD) and hazardous alcohol use. Participation in this study will last approximately 56 weeks.

NCT07219966 Phase: 3 Started: 2025-10-15

The purpose of this study is to see if brenipatide when compared to a placebo works and is safe for participants with moderate-to-severe Alcohol Use Disorder (AUD). Participation in this study will last approximately 56 weeks.

NCT05474989 Phase: 2 Started: 2026-01-27

Lysergic acid diethylamide (LSD) was investigated in numerous clinical trials during the 1950s and 1960s. Specifically, the use of LSD in the treatment of AUD was investigated extensively. A pooled analysis of six historical clinical trials demonstrated that a single dose of LSD significantly reduce...

NCT07148843 Phase: 2/3 Started: 2026-11-01

Cannabidiol (CBD), one of the most prevalent cannabinoids in cannabis (marijuana) has been shown to reduce alcohol withdrawal symptoms in laboratory animals. In people without alcohol use disorder (AUD), CBD has been show to be effective in reducing anxiety, sleep problems, and seizures; all of thes...

NCT05305404 Phase: Early 1 Started: 2022-03-11

This is a double-blind, placebo-controlled, proof of concept laboratory study to recruit N=70 (35 Males / 35 Females) non-treatment seeking, heavy drinkers with alcohol use disorder (AUD). It is hypothesized that randomization to 1.5mgs dexamethasone versus placebo will decrease alcohol craving duri...

NCT04135846 Phase: 2 Started: 2019-08-19

The goal of this research is to replicate findings previously conducted in a pilot trial and to understand, mechanistically, the role of stress in the development of AUD pharmacotherapies that target noradrenergic blockade.

NCT07214207 Phase: 2 Started: 2025-12-04

The goal of this clinical trial is to learn if, how, and for whom suvorexant (SUV) works to treat alcohol use disorder (AUD). The main questions it aims to answer are: * Is SUV effective for AUD? * Does SUV dampen stress reactivity? * Can the researchers develop a biomarker for SUV treatment respons...

NCT07218354 Phase: 3 Started: 2026-07-28

This clinical trial aims to test the effectiveness and safety of semaglutide, a GLP-1 receptor agonist, in treating moderate to severe alcohol use disorder (AUD) in Veterans. Participants who qualify will be randomly assigned to receive either semaglutide injections or placebo injections over a 24-w...

NCT06512389 Phase: 2 Started: 2024-08-16

This human laboratory study aims to assess the effects of cannabidiol on alcohol consumption and craving in participants with alcohol use disorder. In this double-blind within-subject placebo-controlled crossover trial, participants will be randomized to receive both cannabidiol and placebo with a 2...

NCT07279558 Phase: 2 Started: 2026-04-21

The goal of this study is to learn how CBD affects drinking in people who drink alcohol regularly. Researchers want to see if CBD can help people drink less and reduce problems related to alcohol use.

NCT06712602 Phase: 1 Started: 2025-02-01

The goal of this study is to learn if PT150 can reduce the behavioral and physical effects of stress, alcohol, and alcohol use in people with alcohol use disorder.

NCT06319872 Phase: 1 Started: 2025-05-19

Oral disulfiram (Antabuse®) has been shown to improve image-forming vision in animal models with retinal degeneration due to its ability to decrease Retinoic Acid synthesis and consequently reduce hyperactivity in the inner retina. The investigator will aim to evaluate the impact of oral disulfiram ...

NCT07510113 Phase: N/A Started: 2025-12-15

Alcohol Use Disorder (AUD) is a common condition that can affect physical and mental health. Current treatments do not work for everyone, and new approaches are needed. The primary aim of this study is to assess whether taking a specific probiotic supplement (a type of "good bacteria") is a feasible...

NCT05943665 Phase: 2 Started: 2024-02-06

The study investigators are conducting the first open label pilot trial of MDMA-assisted therapy (MDMA-AT) with a comorbid sample of military veterans with a comorbid diagnosis of Alcohol Use Disorder (AUD) and Post-Traumatic Stress Disorder (PTSD). This novel experimental treatment package consists...


Agents Found By Disease-Level Search

Searched directly from “Alcohol Use Disorder” via ClinicalTrials.gov interventions and Open Targets' disease→drug data — independent of the 7-gene target panel above. This surfaces agents whose mechanism doesn't route through a curated gene (combination therapies, standard-of-care drugs, targets outside the panel).

40 agents shown (approved or with trial evidence) — 37 not found by the gene-target search above.

AlcoholNOT in gene-target list

· 3 trials · source: ClinicalTrials.gov
NCT06326684 NCT02046200 NCT03216954

N-acetylcysteineNOT in gene-target list

· 3 trials · source: ClinicalTrials.gov
NCT02791945 NCT05408247 NCT03216954

Brief interventionNOT in gene-target list

· 2 trials · source: ClinicalTrials.gov
NCT00423904 NCT01966432

Treatment as UsualNOT in gene-target list

· 2 trials · source: ClinicalTrials.gov
NCT02530645 NCT00675961

SuvorexantNOT in gene-target list

· 2 trials · source: ClinicalTrials.gov
NCT06326684 NCT06326684

Standard therapy for AUDNOT in gene-target list

· 1 trial · source: ClinicalTrials.gov
NCT04057534

Standard therapy for TUDNOT in gene-target list

· 1 trial · source: ClinicalTrials.gov
NCT04057534

PromillekollNOT in gene-target list

· 1 trial · source: ClinicalTrials.gov
NCT02064998

PartyPlannerNOT in gene-target list

· 1 trial · source: ClinicalTrials.gov
NCT02064998

TeleCoachNOT in gene-target list

· 1 trial · source: ClinicalTrials.gov
NCT02064998

LacosamideNOT in gene-target list

· 1 trial · source: ClinicalTrials.gov
NCT03271528

Prize Contingency Management for Alcohol AbstinenceNOT in gene-target list

· 1 trial · source: ClinicalTrials.gov
NCT02135237

Standard CareNOT in gene-target list

· 1 trial · source: ClinicalTrials.gov
NCT02135237

OnTrackNOT in gene-target list

· 1 trial · source: ClinicalTrials.gov
NCT02530645

W-SUDsNOT in gene-target list

· 1 trial · source: ClinicalTrials.gov
NCT04974645

ZonisamideNOT in gene-target list

· 1 trial · source: ClinicalTrials.gov
NCT05134857

Acamprosate

· 1 trial · source: ClinicalTrials.gov
NCT00330486

Naltrexone 380 MGNOT in gene-target list

· 1 trial · source: ClinicalTrials.gov
NCT04562779

Ketamine Hydrochloride

· 1 trial · source: ClinicalTrials.gov
NCT04562779

Enhanced linkageNOT in gene-target list

· 1 trial · source: ClinicalTrials.gov
NCT04562779

ITCNOT in gene-target list

· 1 trial · source: ClinicalTrials.gov
NCT07519759

Naltrexone

· 1 trial · source: ClinicalTrials.gov
NCT00675961

Cannabis (High% THC) (Inhaled)NOT in gene-target list

· 1 trial · source: ClinicalTrials.gov
NCT04230460

Cannabis (Very High% THC) (Inhaled)NOT in gene-target list

· 1 trial · source: ClinicalTrials.gov
NCT04230460

Alcohol (oral)NOT in gene-target list

· 1 trial · source: ClinicalTrials.gov
NCT04230460

NTX-2001NOT in gene-target list

· 1 trial · source: ClinicalTrials.gov
NCT07520292

CBT + EFTNOT in gene-target list

· 1 trial · source: ClinicalTrials.gov
NCT03551704

CBT + EFT + CMNOT in gene-target list

· 1 trial · source: ClinicalTrials.gov
NCT03551704

Varenicline Tartrate 1 mg b.i.dNOT in gene-target list

· 1 trial · source: ClinicalTrials.gov
NCT04167306

Bupropion Hydrochloride 150 mg b.i.dNOT in gene-target list

· 1 trial · source: ClinicalTrials.gov
NCT04167306

PioglitazoneNOT in gene-target list

· 1 trial · source: ClinicalTrials.gov
NCT05107765

IvermectinNOT in gene-target list

· 1 trial · source: ClinicalTrials.gov
NCT02046200

RopivacaineNOT in gene-target list

· 1 trial · source: ClinicalTrials.gov
NCT03077919

brief, voluntary substance use interventionNOT in gene-target list

· 1 trial · source: ClinicalTrials.gov
NCT00383838

Instranasal OxytocinNOT in gene-target list

· 1 trial · source: ClinicalTrials.gov
NCT03878316

Dual ProcessingNOT in gene-target list

· 1 trial · source: ClinicalTrials.gov
NCT01320748

Relapse PreventionNOT in gene-target list

· 1 trial · source: ClinicalTrials.gov
NCT01320748

Brief Family-Involved Treatment for Alcohol Use DisorderNOT in gene-target list

· 1 trial · source: ClinicalTrials.gov
NCT05545644

OxytocinNOT in gene-target list

· 1 trial · source: ClinicalTrials.gov
NCT03610633

E-cig useNOT in gene-target list

· 1 trial · source: ClinicalTrials.gov
NCT03449017

Generated by the Open Source Medicine Foundation Biomarker Pipeline — 2026-10-08. Data sources: DGIdb, Open Targets, ChEMBL, PubMed, ClinicalTrials.gov. Not medical advice.